Premium
Treatment of T cell lymphoma in dogs
Author(s) -
Moore Antony S.
Publication year - 2016
Publication title -
veterinary record
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.261
H-Index - 99
eISSN - 2042-7670
pISSN - 0042-4900
DOI - 10.1136/vr.103456
Subject(s) - lymphoma , chop , medicine , canine lymphoma , disease , stage (stratigraphy) , oncology , t cell lymphoma , chemotherapy , gastroenterology , pathology , biology , paleontology
Overall, canine lymphoma remains one of the most chemotherapy‐responsive cancers in the dog. In addition to the stage and the substage of disease, T cell phenotype is the most consistently important prognostic factor. T cell lymphoma (TCL) in dogs is a heterogeneous disease; dogs with a separate entity of indolent TCL can have a considerably better prognosis than dogs with other forms of lymphoma, and indolent TCL may not always require immediate treatment. In contrast, high‐grade TCL is an aggressive disease, and when treated with CHOP‐based protocols, dogs with this high‐grade TCL have a complete remission rate as low as 40 per cent, relapse earlier and have shorter survival time than dogs with a comparable stage, high‐grade B cell lymphoma. This review describes the different disease entities that comprise canine TCL, discusses prognosis for each and treatment options that appear to give the best outcomes.